Systematic review reveals genetic insights and therapeutic strategies for craniofacial fibrous dysplasia, suggesting novel treatments may enhance patient outcomes.
Craniofacial fibrous dysplasia (CFD) is a rare skeletal disorder characterized by the abnormal replacement of normal bone tissue with fibrous tissue. This article provides a systematic review of the latest advancements in the genetic basis, molecular mechanisms, clinical manifestations, and diagnostic and therapeutic strategies of CFD. Elucidate, which leads to bone homeostasis imbalance and fibrotic abnormalities. It focuses on the molecular mechanisms underlying multi-pathway network dysregulation induced by GNAS gene mutations and explores the roles of key molecules like cAMP-response element binding protein, interleukin-6 and Fibroblast growth factor 23 in disease progression. Additionally, it evaluates the limitations of traditional treatments and the translational potential of novel strategies, including targeted therapies, offering a theoretical foundation for clinical practice and future research directions.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: